Topiagen/NicOx discontinue COPD drug
Due to poor results from a Phase IIa study of Topiagen Pharmaceuticals' TPI 1020 in chronic obstructive pulmonary disease, the US drugmaker has decided to discontinue the agent in this indication.
TPI 1020 showed good overall safety and tolerability, although its activity profile was not significantly different from budesonide, a common corticosteroid used in respiratory disorders. The agent is a New Chemical Entity licensed from French firm NicOx SA for respiratory indications.
In light of the poor efficacy results, Topigen and NicOx have decided to discontinue the development of TPI 1020 in COPD and will explore potential opportunities for this compound in other indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze